Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07179692 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started2025-09-12
View on ClinicalTrials.gov ↗

Amendment history

2025-09-28
Study Status, Contacts/Locations v1
Re-verified, no change to tracked fields
2025-09-16
Original filing
Chongqing Precision Biotech Co., Ltd
36 trials monitored
See 1 trial at risk
Lung Cancer
4,033 trials monitored
See 210 trials at risk
Colorectal Cancer
2,904 trials monitored
See 127 trials at risk
Pancreatic Cancer
1,634 trials monitored
See 90 trials at risk
and 2 more diseases
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Trial Details
NCT Number NCT07179692
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions Lung Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreas Cancer
Enrollment 108 participants
Start Date 2025-09-12
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-02